KPTI
Karyopharm Therapeutics Inc
1.80$
-3.3%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 26,256.3% | 39,097.6% | 56,453.2% | 6,683.7% | 531.9% | 5.9% | 2.5% | 1.6% | 3.3% | 3.4% | 4.1% | 4.1% | |
| -26,156.3% | 100.0% | 100.0% | 100.0% | -431.9% | 94.1% | 97.5% | 98.4% | 96.7% | 96.6% | 95.9% | 95.9% | |
| 26,256.3% | 39,097.6% | 56,453.2% | 6,683.7% | 531.9% | 299.2% | 139.5% | 76.7% | 94.6% | 95.0% | 98.6% | 86.0% | |
| 6,964.2% | 8,632.8% | 15,550.6% | 1,549.5% | 161.0% | 257.8% | 117.0% | 68.6% | 92.6% | 90.3% | 79.5% | 72.0% | |
| 33,220.5% | 47,730.4% | 72,003.9% | 8,233.2% | 693.0% | 557.0% | 256.5% | 145.2% | 187.2% | 185.3% | 178.1% | 158.0% | |
| -33,120.5% | -47,630.4% | -71,903.9% | -8,133.2% | -593.0% | -462.9% | -159.0% | -46.8% | -90.5% | -88.7% | -82.2% | -62.1% | |
| 0.4% | 358.0% | 840.3% | 100.7% | 8.2% | 38.3% | 25.1% | 12.4% | 15.9% | 16.3% | 25.8% | 31.4% | |
| -33,090.4% | -47,272.4% | -71,063.6% | -8,032.5% | -588.0% | -488.0% | -181.3% | -59.0% | -105.0% | -97.8% | -52.6% | -134.2% | |
| -30.1% | -358.0% | 90.3% | 3.9% | 0.1% | 0.1% | 0.3% | 0.1% | 0.2% | 0.2% | 0.0% | 0.0% | |
| -33,090.4% | -47,272.4% | -71,153.9% | -8,036.4% | -588.1% | -488.1% | -181.6% | -59.1% | -105.2% | -98.0% | -52.6% | -134.2% | |
| -32,949.3% | -47,376.8% | -71,438.3% | -8,088.8% | -577.4% | -447.3% | -155.3% | -46.2% | -88.7% | -81.1% | -26.6% | -102.6% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.